Parkinson’s disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. The global Parkinson’s Disease Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Parkinson’s Disease Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Parkinson’s Disease Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Parkinson’s Disease Drugs in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes their Parkinson’s Disease Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
Global Market Outline: Parkinson’s Disease Drugs Market
Parkinson’s disease refers to a progressive neurological disorder that affects the body movements of the patient. There are five stages of Parkinson’s disorder, which can affect the individual’s facial expressions, hand and leg movements, and these worsen over time. The symptoms of this disease include tremor, rigidity, bradykinesia, and postural instability. The global Parkinson’s disease drug market is estimated to upscale at a fast pace during the forecast period, as per the latest analysis. This can be primarily owed to the rising prevalence of Parkinson’s disease.
The following manufacturers are covered:
F. Hoffmann-La Roche
Teva Pharmaceutical Industries
Valeant Pharmaceuticals International
In addition, a combination of treatments that aids in the prolonged action of unremitting dopaminergic stimulation medicines, gene therapy, as well as neural transplantation is expected to boost the global Parkinson’s disease drug market during the forecast period. A rise in the patient pool and increased diagnosis rates and technologies to diagnose such disorders are other factors behind the growth of the global Parkinson’s disease drug market. As per the Parkinson’s Disease Foundation, there are around 10 million people all over the world who are suffering from Parkinson’s disease. Such a high frequency and presence of the disease is mostly found in higher rates in the development countries. Within the United States around 60,000 new cases of Parkinson’s disease are diagnosed every year.
Presently, the only drugs available in the market are symptomatic drug treatments. Further, such symptoms are diagnosed at later stages when most of the dopamine-producing cells have lost their function. Such a scenario has posed a need to innovate drugs which aid in the improvement of the disease and eventual cure of the same. Such a need has encouraged many new market entrants and a rising investments in the research and development of innovative drugs. All these factors are also expected to drive the global Parkinson’s disease drug market over the forecast period.
Segment by Type
Segment by Application
The global Parkinson’s disease drug market is segmented by type, application, and region. Based on type, the Parkinson’s disease drug market is segmented into clinical and experimental. Based on application, the global Parkinson’s disease drug market is segmented into treatment and prevention.
Detailed Regional Analysis
The global Parkinson’s disease drug market is segmented into the regions of North America, Latin America, Europe, Asia Pacific, as well as the Middle East & Africa. North America was at the forefront in the Parkinson’s disease drug market at the beginning of the assessment period. The region is also assessed to retain its dominant place in the global market through the forecast period. This can be owed to the increasing prevalence of this disorder in the region. Additionally, the region is facilitated with a well-established healthcare infrastructure, which is aiding in the market growth.
Asia Pacific is estimated to witness a surging growth in the global Parkinson’s disease drug market during the assessment period. This can be causative to the presence of untapped opportunities in the region.
Oct 2019: Indoco Remedies recently received approval from the USFDA for Rasagiline tablets which are used in the treatment of Parkinson’s disease.
Table of Contents
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 United States
9 Southeast Asia
11 Central & South America
12 International Players Profiles
13 Market Forecast 2018-2025
14 Analyst’s Viewpoints/Conclusions
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349